Literature DB >> 18706349

Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases.

Anna-Luise A Katzenstein1, Sanjay Mukhopadhyay, Jeffrey L Myers.   

Abstract

Usual interstitial pneumonia is an almost uniformly fatal form of fibrosing interstitial lung disease. It is the most common idiopathic interstitial pneumonia, and currently, there is no effective therapy. Lung biopsy is often needed for diagnosis, and pathologists must be able to recognize its features and distinguish it from other interstitial lung diseases that have a better prognosis and a more favorable response to therapy. This review is an attempt to clarify the diagnostic pathologic features of usual interstitial pneumonia and to provide guidelines for its distinction from other interstitial lung diseases that enter the differential diagnosis.

Entities:  

Mesh:

Year:  2008        PMID: 18706349     DOI: 10.1016/j.humpath.2008.05.009

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  41 in total

1.  Lipopolysaccharide promotes pulmonary fibrosis in acute respiratory distress syndrome (ARDS) via lincRNA-p21 induced inhibition of Thy-1 expression.

Authors:  Wen-Qin Zhou; Peng Wang; Qiu-Ping Shao; Jian Wang
Journal:  Mol Cell Biochem       Date:  2016-07-08       Impact factor: 3.396

2.  Bronchoalveolar lavage total cell count in interstitial lung diseases--does it matter?

Authors:  Joanna Domagała-Kulawik; Tomasz Skirecki; Marta Maskey-Warzechowska; Hanna Grubek-Jaworska; Ryszarda Chazan
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

Review 3.  Cellular mechanisms of tissue fibrosis. 7. New insights into the cellular mechanisms of pulmonary fibrosis.

Authors:  Christina E Barkauskas; Paul W Noble
Journal:  Am J Physiol Cell Physiol       Date:  2014-04-16       Impact factor: 4.249

Review 4.  Does chronic microaspiration cause idiopathic pulmonary fibrosis?

Authors:  Joyce S Lee; Harold R Collard; Ganesh Raghu; Matthew P Sweet; Steven R Hays; Guilherme M Campos; Jeffrey A Golden; Talmadge E King
Journal:  Am J Med       Date:  2010-04       Impact factor: 4.965

5.  Hypermethylation-mediated silencing of p14(ARF) in fibroblasts from idiopathic pulmonary fibrosis.

Authors:  José Cisneros; James Hagood; Marco Checa; Blanca Ortiz-Quintero; Miguel Negreros; Iliana Herrera; Carlos Ramos; Annie Pardo; Moisés Selman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-06-15       Impact factor: 5.464

6.  CXCL17 is a mucosal chemokine elevated in idiopathic pulmonary fibrosis that exhibits broad antimicrobial activity.

Authors:  Amanda M Burkhardt; Kenneth P Tai; Juan P Flores-Guiterrez; Natalia Vilches-Cisneros; Karishma Kamdar; Oralia Barbosa-Quintana; Ricardo Valle-Rios; Peter A Hevezi; Joaquin Zuñiga; Moises Selman; André J Ouellette; Albert Zlotnik
Journal:  J Immunol       Date:  2012-05-18       Impact factor: 5.422

7.  Differential role of the Fas/Fas ligand apoptotic pathway in inflammation and lung fibrosis associated with reovirus 1/L-induced bronchiolitis obliterans organizing pneumonia and acute respiratory distress syndrome.

Authors:  Andrea D Lopez; Sreedevi Avasarala; Suman Grewal; Anuradha K Murali; Lucille London
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

Review 8.  Idiopathic pulmonary fibrosis: early detection and referral.

Authors:  Justin M Oldham; Imre Noth
Journal:  Respir Med       Date:  2014-04-04       Impact factor: 3.415

9.  Signal recognition particle (SRP) positive myositis in a patient with cryptogenic organizing pneumonia (COP).

Authors:  Felix Wantke; Meinhard Kneussl; Marianne Hubner; Kurt Derfler; Thomas Brücke; Sabine Schmaldienst
Journal:  Rheumatol Int       Date:  2009-07-29       Impact factor: 2.631

10.  Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma.

Authors:  Flávio Henrique Ferreira Galvão; José Osmar Medina Pestana; Vera Luiza Capelozzi
Journal:  Cancer Chemother Pharmacol       Date:  2010-02       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.